Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 4/20 | 0.54 |
| ▸ | PDE4A | P27815 | 17/20 | 0.48 |
| ▸ | PDE2A | O00408 | 4/20 | 0.48 |
| ▸ | PDE8A | O60658 | 3/20 | 0.48 |
| ▸ | PDE5A | O76074 | 3/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.48 |
| ▸ | PDE11A | Q9HCR9 | 3/20 | 0.48 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.48 |
| ▸ | PDE9A | O76083 | 2/20 | 0.48 |
| ▸ | PDE1A | P54750 | 1/20 | 0.46 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL194043 | 0.90 | PDE1B (0.58) | PDE1BPDE4APDE2APDE8APDE5A | |
| SCHEMBL193817 | 0.89 | PDE1B (0.57) | PDE1BPDE4APDE2APDE8APDE5A | |
| SCHEMBL8059501 | 0.87 | PDE1B (0.57) | PDE1BPDE4APDE2APDE8APDE5A | |
| SCHEMBL3087675 | 0.86 | PDE1B (0.67) | PDE1BPDE4APDE2APDE8APDE5A | |
| SCHEMBL8059763 | 0.84 | PDE1B (0.55) | PDE1BPDE4APDE2APDE8APDE5A | |
| SCHEMBL8057140 | 0.84 | PDE1B (0.55) | PDE1BPDE4APDE2APDE8APDE5A | |
| SCHEMBL193818 | 0.81 | PDE1B (0.57) | PDE1BPDE4APDE2APDE8APDE5A | |
| SCHEMBL8057143 | 0.81 | PDE1B (0.39) | PDE1BPDE4APDE2APDE8APDE5A | |
| SCHEMBL714893 | 0.81 | PDE1B (0.56) | PDE1BPDE4APDE2APDE8APDE5A | |
| SCHEMBL3085971 | 0.80 | PDE1B (0.62) | PDE1BPDE4APDE2APDE8APDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10238660-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10010553-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20160375028-A1 | ORGANIC COMPOUNDS | FIENBERG ALLEN A (US) | 2016-12-29 | — | — | US | disclosed |
| US-9468637-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150197524-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197524-A1 | ORGANIC COMPOUNDS | LI PENG (US) | 2015-07-16 | — | — | US | disclosed |
| US-8846693-B2 | Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846693-B2 | Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
| US-20100273753-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273753-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2010-10-28 | — | — | US | disclosed |
| WO-2009073210-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE1B 27/4885PDE4A 2/4885PDE2A 4/4885 |
| US-20100273753-A1 | ORGANIC COMPOUNDS | OPRD1, PGR, HTR1D | PDE1B 147/4885PDE4A 83/4885PDE2A 104/4885 |
| US-20150197524-A1 | ORGANIC COMPOUNDS | OPRD1, HTR1D, DRD1 | PDE1B 115/4885PDE4A 73/4885PDE2A 83/4885 |
| US-10010553-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | PDE1B 27/4885PDE4A 2/4885PDE2A 4/4885 |
| US-20160375028-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE1B 27/4885PDE4A 2/4885PDE2A 4/4885 |
| US-10238660-B2 | Organic compounds | PDE5A, PDE4A, PDE3A | PDE1B 27/4885PDE4A 2/4885PDE2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.